This document discusses Rhesus isoimmunization, which occurs when a Rh-negative mother develops antibodies against Rh-positive fetal red blood cells. It covers the epidemiology, pathophysiology, causes including the "grandmother effect", investigations such as the Kleihauer-Betke and Coombs' tests, management of sensitized mothers through surveillance and potential fetal transfusions, and treatment of affected newborns including phototherapy and exchange transfusions. Prevention relies on administering Rhogam prophylaxis to unsensitized Rh-negative mothers.
Rh incompatibility or iso-immunization is very uncommon. This presentation deals with some basics about blood groups and pathogenesis of it. This will be useful for under and postgraduates in the field of obstetrics.
Rh incompatibility or iso-immunization is very uncommon. This presentation deals with some basics about blood groups and pathogenesis of it. This will be useful for under and postgraduates in the field of obstetrics.
Prelabour Rupture of Membrane (PROM) by Sunil Kumar Dahasunil kumar daha
Please find the power point on Prelabour Rupture of Membrane (PROM). I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Explains the inflammatory process of endometrium,its causes and its two clinical variants as acute and chronic endometritis.
Describes the pathology of its two types with histologic perspective.
Prelabour Rupture of Membrane (PROM) by Sunil Kumar Dahasunil kumar daha
Please find the power point on Prelabour Rupture of Membrane (PROM). I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Explains the inflammatory process of endometrium,its causes and its two clinical variants as acute and chronic endometritis.
Describes the pathology of its two types with histologic perspective.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
2. Outline
• Introduction to ABO And Rhesus Blood Group System
• Epidemiology
• Causes
• Grandmother effect
• Pathophysiology
• Investigations
• management
• Prevention
3. Introduction
• Isoimmunization /alloimmunization:
• Production of antibodies in response to an antigen derived from another
individual of the same species
• Rhesus Isoimmunization
• Maternal antibody production in response to fetal red blood cell Rh
antigen which occurs when mother Rh negative ,fetus Rh postive.
• Sensibilized : producing detectable antibodies only in a subsequent
pregnancy (Bowman, 1985).
4. ABO blood group system
• 4 blood types (A, B, AB & O)
• additionally classified according to the presence or absence of Rh
factor
5. The Rhesus Factor
• A group of antigens that may or may not be present on the surface of the
red blood cells. the most common Include C,c, D,d, e and E antigens
• The 2 responsible genes: RHD and RHCE are located on the short arm
of x-some 1 and are inherited together, independent of other BG genes.
• D antigen is the most immunogenic and determines Rh positivity i.e
Rh positive, those who lack the D antigen are Rh negative.
• Fetal Rh-antigen are present by 38th day after conception.
6. The Rhesus Factor
• Rh alleles: Cc, Dd and Ee. D antigen, the most potent, its presence or
absence denotes an individual to be Rh +ve or –ve.
• DD homozygous, Dd-heterozygous, dd- negative.
8. Abo Incompatibility
• ABO incompatibility describes an immune reaction that occurs in the
body if two blood samples of different, incompatible ABO types are
mixed together, when these RBC act as antigen & an immune response
is triggered.
• It affects newborns whose mothers are blood type O, and who have a
baby with type A, B or AB.
• Other blood group systems; Kidd, Diego, Kell, MNS, Duffy , Lewis,
Scianna, Dombrock, Colton, Gerbich, Lutheran, I
11. Epidemiology
• It is more frequent among Caucasians descent (15-17%), Africans (4-8%),
Asian descent (0.1-0.3%). (Bhutani et al 2013)
• Prevalence in Uganda is not known, found to be 2.2% in south western
Uganda (Natukunda et al 2011)
• Without anti-D immune globulin prophylaxis, a D-negative woman
delivered of a D-positive, ABO-compatible newborn has a 16% likelihood
of developing alloimmunization. 2% will become sensitized by the time of
delivery, 7 % by 6 months postpartum, and the remaining 7% will be
“sensibilized”( Boweman, 1985)
12. • Thus, affection of the baby due to Rh incompatibility is low considering
the increased number of Rh+ babies delivered to Rh-ve mothers.
• Insufficient placental transfer of fetal antigens or maternal antibodies.
• Inborn inability to respond to the Rh antigen stimulus.
• Immunological non-responder—as found in 30% of Rh-negative women.
• ABO incompatibility has a protective effect against the development of Rh
sensitization. significant if mother is type O, father is type A, B or AB
• Variable antigenic stimulus of the D antigen which depends on the Rh
genotype of the fetal blood, e.g. CDe/cde genotype.
• Volume of fetal blood entering into the maternal circulation (0.1 mL is
considered as critical sensitizing volume).
13. Early pregnancy loss
abortion- elective or spont.
molar pregnancy
Ectopic pregnancy
Fetal death (any trimester)
Procedures
Fetal blood sampling, CVS, Amniocentesis
Cesarean Section/ vaginal delivery
blood transfusion /bone marrow transplants
injections with contaminated needles
Idiopathic :
? Vanishing twin, grandmother theory
Other
Idiopathic
Maternal trauma/APH
Manual placental removal
External version
Causes of Fetomaternal Hemorrhage that May Incite Rh Isoimmunization
14. The Grandmother Effect
• In virtually all pregnancies, small amounts of mat. blood enter the fetal
circulation. PCR has been used to identify mat D+ve DNA in peripheral
blood from preterm and full-term D-ve newborns (Lazar, 2006).
• Thus, it’s possible for a RhD- female fetus exposed to mat. rhD+ red cells
to develop sensitization. When such an individual reaches adulthood, she
may produce anti-D antibodies even before or early in her 1st pregnancy.
• mechanism called the grandmother effect or theory bse the fetus in the
current pregnancy is jeopardized by mat. ab that were initially provoked
by his or her grandmother’s erythrocytes.
15. Pathophysiology
• There is normally no mixing of fetal & maternal blood during pregnancy.
• When the placenta begins to separate & the chorionic villi tear, the risk of
feto-maternal transfusion is increased.
• Rh antigens of the fetal red cells (0.1ml) stimulate the prodn of maternal
antibodies(become detectable after 6 months)
• The 1st encounter may not result in Ig M but no sensitization, on 2nd
encounter Ig G are produced and these cross the placenta
16. Pathophysiology
• maternal IgG crosses the placenta barrier & enters into fetal circulation
while IgM does not cross. Once formed the antibodies are permanent.
• If the fetus is Rh positive, the antibody becomes attached to the antigen
sites on the surface of the erythrocytes.
• The affected cells are rapidly removed from the circulation by the RES
resulting in fetal anemia.
• Hyperplasia of the placental tissue occurs in an effort to increase the
transfer of oxygen but the available fetal red cells
17.
18.
19. Fetal effects
• There is no risk 1st trimester abortion in RH Isoimmunization unless
a/w other congenital anomalies
• Effects of RH Isoimmunization is not evident till second trimester of
pregnancy only after 2nd trimester the reticuloendothelial system of
fetus is developed and RH antigens are formed in utero
• It has been found that the amount of FMH is very minute (around 0.03
mL) during 1st and 2nd trimester however it may be as high as 25 mL
during 3rd trimester (Puangsricharern 2007 : Bhatnagar 1980)
20. Fetal effects
• Destruction of fetal RBC’s cause fetal anaemia which is continuous during
intrauterine life. Due to anemia, the fetal growth is retarded
• Erythroblastosis fetalis. Overproduction of immature fetal and neonatal red
cells, now called Hemolytic disease of the fetus and newborn(HDFN)
• Hydrops fetalis: abnormal collection of fluid in more than one area of the
fetal body is termed hydrops fetalis (scalp edema, pleural effusion,
pericardial effusion, ascites, and skin edema). Buddha’ sign on ultrasound.
• tissue hypoxia and acidosis eventually lead to intra uterine fetal death.
21. Neonatal Effects
• Congenital hemolytic anemia: slow hemolysis , the anemia develops
slowly within 1st few weeks of life, the jaundice is not usually evident.
Hemolysis continues up to 6 weeks due to antibody presence
• Hyperbilirubinemia, if timely actions are not taken the hyperbilirubinemia
results in deposition of bilirubin in the basal cerebral ganglia leading to
kernicterus. Due to relative immaturity of function of the liver
• Icterus gravid neonatorum. The fetus is born alive without jaundice but
develops it within 24 h.
• Progressive anemia can lead to congestive cardiac failure and death
22. Maternal effects
• There is increased incidence of:
• Preeclampsia;
• Polyhydramnios;
• Big size baby with its hazards;
• Hypofibrinogenemia -prolonged retention of dead fetus in uterus;
• Postpartum hemorrhage - big placenta and blood coagulopathy;
• “maternal syndrome”- generalized edema, proteinuria and pruritus due
to cholestasis.
23. Investigations
• Blood grouping and Rhesus typing
• Indirect Combs test (ICT): maternal antibody screen
• Paternal zygosity testing (PCR)
• Cell free fetal DNA testing
• Kleihauer-Betke test: amount of fetal blood in maternal circulation.
• amnionic fluid Spectrophotometry: also known as the ΔOD450 test, is
no longer recommended (SMFM, 2015)
• Fetal blood sampling
• Cord blood examn: ABO , Rh, DCT, Hb and Bilirubin
24. If severe fetal anemia, a sinusoidal heart rate pattern may develop
25. Direct Coombs’ Test
• used to detect these antibodies or complement proteins that are bound
to the surface of RBC.
• A blood sample is taken & the RBCs are washed & then incubated
with antihuman globulin[also known as coombs’ reagent].
• If this produces agglutination [clumping together] of RBCs, The
Direct Coombs’ Test Is Positive.
26.
27. Indirect Coombs’ Test
• It detects antibodies against RBCs that are present unbound in the
patient’s serum.
• In this case serum is extracted from the blood sample taken from the
patient.
• Then the serum is incubated with the RBC of known reference values
from other patient blood samples.
• If this produces agglutination of RBCs, The Indirect Coombs’ Test Is
Positive.
28.
29. KB test
• Fetal red cells in the maternal circulation can be identified by use of
the acid elution principle first described by Kleihauer, Brown, and
Betke
• Fetal erythrocytes contain HbF, which is more resistant to acid elution
than HbA. After exposure to acid, only fetal hemoglobin remains.
• Fetal red cells can then be identified by uptake of a special stain and
quantified on a peripheral smear
• If there are 80 fetal RBCs in 50 low power fields in mat peripheral
blood films, it rep. a transplacental hemorrhage to the extent of 4 mL
of fetal blood.
30.
31. Diagnosis
The essentials of diagnosis are:
1. The mother must be Rh negative.
2. Presence of maternal Rh antibodies as shown by a positive
indirect coombs’ test on mother’s blood.
3. Maternal antibody titre posing risk to fetus.
4. History of birth of previous affected baby.
5. Fetal cord blood shows low level of Hb at birth & raised
bilirubin
32. Management
• Fetal Risk Assessment
• maternal Antibody titer
surveillance
• Ultrasound monitoring of the
fetal MCA PSV if a critical
antibody titer is reached
• Delivery timing and mode
33.
34. Critical titer
• The critical titer is the level at which significant fetal anemia could
potentially develop.
• This may be different for each antibody, is determined individually by
each laboratory, and usually ranges between 1:8 and 1:32.
• the critical titer for anti-D antibodies is 1:16, a titer ≥1:16 indicates the
possibility of severe hemolytic disease.
• In any pregnancy in which the antibody titer has reached a critical
value, there is no benefit to repeating the titer.
35. Management of Rh-ve Non-sensitized mother
• Initial evaluation of alloimmunization risk with blood group and Rh factor
, mat antibody screening with indirect coombs test at booking visit
• Monthly ICT till delivery , if positive manage as sensitized
• At 28 weeks give prophylactic 300-μg of anti-D and within 72 hrs after
delivery if rhesus positive newborn
• If immune anti-D ab is detected, prophylaxis is no longer necessary
36.
37. Management Of rh-ve Sensitized Mother
• Sensitization IS by the detection of Rh antibodies in mat, circulation using ICT .
• If alloimmunization is detected and the titer is below the critical value, the titer is
generally repeated every 4 weeks for the duration of the pregnancy (ACOG, 2019a).
• Anti-D antibody titres determined and if titre < 4IU/ml is unlikely to produce severe
fetal disease, if > 4 iu/ml but < 15 iu/ml correlates with a moderate risk of HDFN , if
> 15 iu/ml can cause severe HDFN.
• After the 1st affected pregnancy, the ability to predict fetal anemia from the mat. anti-
D antibody titers is lost and now these pregnancies shd be monitored by MCA-PSV
38.
39. When to administer RHOGAM?
• It binds to fetal RBCs and prevents stimulation of maternal immune system.
• It should be given at 28 wks to all unsensitized Rh-ve mother and postpartum
within 72 hours if the baby’s Blood group is Rh positive.
• In case, where the specified time limit is over (>72hour) She may be given
up to 28 days after delivery to avoid sensitization.
• One 300-μg dose is given for each 15 mL of fetal red cells or 30 mL of fetal
whole blood to be neutralized. 10μg of anti- D should be given for every
additional 0.5 mL of fetal RBCs in maternal circulation.
41. fetal transfusion (intra-uterine transfusion).
• Fetal blood sampling is generally performed if the MCA PSV exceeds the threshold
for severe anemia, with plan for concurrent IUT as needed.
• If the MCA PSV exceeds 1.5 MoM or if hydrops develops or fetal Hct <30% or the
Hb is at least 2 g/dl below the mean for normal fetuses of corresponding GA.
• fresh O-negative doubly packed cells is given to the fetus by intravascular or
intraperitoneal route. The volume transfused = (Gest age – 20) × 10 mL
• Fetal transfusion is typically performed prior to 34 to 35 WOG. Later in gestation,
the benefits of transfusion may be outweighed by the risks of delaying delivery..
42. Obstetric management
• Aim is to carry beyond 34 weeks. Mildly affected fetus – May wait till
term and for spontaneous onset of labour.
• Moderately affected fetus – either vaginally or by LSCS before term.
• Severely affected fetus – LSCS is preferred when fetal parameters poor
• Care at delivery: Close monitoring through out the first stage, Clamp the
cord immediately, Gentle handling of the uterus, Cord blood is collected
for neonatal group and type, Hb, haematocrit, bilirubin and direct
Coombs
• Avoid the following: Uterine massage, Manual removal of placenta ,
Ergometrine
43. Postnatal Management
• The neonates may be born with anemia, hepato-spleenomegaly &
ascites and rapidly develop hyperbilirubinemia.
• These infants are hypo-coagulable & have a tendency of developing
hypoglycemia.
• The presence of positive DCT is sufficient to confirm the diagnosis in
an Rh positive neonate born to a sensitized Rh negative women.
44. Treatment of neonatal anemia
• In those infants who exhibit only anemia, fresh packed red cells are
given to correct this defect.
• The management of hydrops fetalis which is the several form of the
disorder is usually done by the rapid correction of anemia by small
exchange transfusion 20 to 40 ml/kg body wt raises the hematocrit
sufficiently.
45. Treatment Of Neonatal Jaundice.
• Phototherapy exposure of neonates to light with wave length of 420-
470mm results in addition of bilirubin & conversion to products that
are water soluble, are not neurotoxic and which can be excreted via
stool and urine.
• It takes 12-24 hrs to be effective.
46. Exchange transfusion:
• Helps by removing unconjugated bilirubin & Rh positive cells coated with
antibodies.
• Traditionally double volume exchange transfusion done via umbilical vein
using group specific negative blood cross matched with mothers serum
effectively.
• Indications: Rh-positive with direct Coombs’ test positive babies having:
• (i) Cord blood bilirubin level > 4 mg/dl and hemoglobin level is < 11 gm/dl.
• (ii) Rising rate of bilirubin over 1 mg/dl/hour despite phototherapy.
• (iii) Total bilirubin level is 20 mg/dl or more.
47. Prevention Of Maternal Isoimmunization
• There are 3 ways of preventing a women from producing rhesus
antibodies.
Avoiding transfusion of Rh positive blood.- avoids sensitization
Prevention of avoidable feto-maternal transfusion- avoid
transplacental amniocentesis
Administration of ANTI D immunoglobulin
48. Thank you for listening
queries, supplements are welcome
References
• Williams Obstetrics, 26th edition, 2022
• RCOG, The Management of Women with Red Cell Antibodies during
Pregnancy. Green-top Guideline No. 65, May 2014.
• DC Dutta’s, Text book of obstetrics,8th ed, 2015
• Smart Study Series: Obstetrics and Gynecology, 3/e Bhojani
• Up To Date 2023
• Agarwal, K., Rana, A. & Ravi, A.K. Treatment and Prevention of Rh
Isoimmunization.(2014). https://doi.org/10.1007/s40556-014-0013-z
• Gabbes obs/self asssesments obstetrics, Holland/brews Manuel of obstetrics
Editor's Notes
The ABO blood group antigens may also sometimes
cause isoimmunization in a mother having O positive blood group and carrying an A, B or AB positive fetus. But for practical purposes these antigens do not cause significant fetal hemolysis and fetal anemia.
Small amount of FMH (total of less than 15 mL) is inevitable during the course of pregnancy.
MCA peak systolic velocity increases signifcantly beyond 34 weeks’ gestation and stems rom the
normal rise in cardiac output that develops at this gestational age
Serial measurement of the peak systolic velocity of the fetal MCA is the recommended test to detect fetal anemia (SMFM, 2015a)